Evidence map›Paper›PMID 16301544›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Charting biologically relevant chemical space: a structural classification of natural products (SCONP).

Marcus A Koch, Ansgar Schuffenhauer, Michael Scheck, Stefan Wetzel, Marco Casaulta, Alex Odermatt, Peter Ertl, Herbert Waldmann

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 551 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Scaffold Remodelling of Diazaspirotricycles Enables Synthesis of Diverse spChemistry (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Chemical Evolution of Natural Product Structure.Journal of the American Chemical Society · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. Pseudo Natural Products-Chemical Evolution of Natural Product Structure.Angewandte Chemie (International ed. in English) · 2021
    Review

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Marcus A KochDepartment of Chemical Biology, Max Planck Institute of Molecular Physiology, Dortmund, Germany.
Ansgar Schuffenhauer
Michael Scheck
Stefan Wetzel
Marco Casaulta
Alex Odermatt
Peter Ertl
Herbert Waldmann
Novartis (Switzerland) · CHUniversity of Bern · CHMax Planck Institute of Molecular Physiology · DENovartis Institutes for BioMedical Research

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of small molecules that fall within the biologically relevant subfraction of vast chemical space is of utmost importance to chemical biology and medicinal chemistry research. The prerequirement of biological relevance to be met by such molecules is fulfilled by natural product-derived compound collections. We report a structural classification of natural products (SCONP) as organizing principle for charting the known chemical space explored by nature. SCONP arranges the scaffolds of the natural products in a tree-like fashion and provides a viable analysis- and hypothesis-generating tool for the design of natural product-derived compound collections. The validity of the approach is demonstrated in the development of a previously undescribed class of selective and potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 with activity in cells guided by SCONP and protein structure similarity clustering. 11beta-hydroxysteroid dehydrogenase type 1 is a target in the development of new therapies for the treatment of diabetes, the metabolic syndrome, and obesity.

Indexed as

Databases, FactualSoftware11-beta-Hydroxysteroid Dehydrogenase Type 1Biological ProductsChemistryDrug DesignInformaticsProtein Conformation11-beta-Hydroxysteroid Dehydrogenase Type 1Biological ProductsHSD11B1 protein, human

Identifiers

PMID16301544
PMCPMC1297657
OpenAlexW2041620837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.